About Us

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has three approved products in collaboration, a broad clinical and pre-clinical product pipeline and four proprietary next generation antibody technologies.

About Genmab

Company overview

More information about our company

Core Values

Core purpose and values

We have a strong company culture: What drives our employees?


Senior leadership

Experienced international management group



Read more about our past